Monoclonal antibody response in refractory Multiple Myeloma with extramedullary involvement

Monoclonal antibodies emerge as highly active compounds in the treatment of Multiple Myeloma leading to FDA approval of two molecules just in 2015. In a translational approach, the fully human anti-GRP78 antibody PAT-SM6 was evaluated in vitro and on a first patient who experienced partial remission after treatment with PAT-SM6 in combination with novel agents.

Dexamethasone-induced cell death is restricted to specific molecular subgroups of Multiple Myeloma

Due to its cytotoxic effect in lymphoid cells, dexamethasone is widely used in the treatment of Multiple Myeloma. However, only a subset of myeloma patients responds to high-dose dexamethasone. Despite the undeniable anti-myeloma benefits of dexamethasone, significant adverse effects have been reported. The anti-tumor effect of dexamethasone was re-evaluated according to the molecular heterogeneity of Multiple Myeloma.